Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 6/20 | 0.46 |
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.46 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 6/20 | 0.44 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.39 |
| ▸ | LCK | P06239 | 1/20 | 0.39 |
| ▸ | HCK | P08631 | 1/20 | 0.39 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL612493 | 0.84 | TTK (0.53) | JAK3JAK2PTK2JAK1TTK | |
| SCHEMBL612990 | 0.79 | JAK2 (0.40) | JAK3JAK2PTK2TTKRET | |
| SCHEMBL613379 | 0.78 | LRRK2 (0.47) | JAK3JAK2PTK2TTKRET | |
| SCHEMBL614638 | 0.77 | JAK2 (0.44) | JAK3JAK2PTK2TTKSRC | |
| SCHEMBL612999 | 0.77 | TTK (0.39) | JAK2JAK1TTKRETSRC | |
| SCHEMBL612998 | 0.77 | TTK (0.39) | JAK2JAK1TTKRETSRC | |
| SCHEMBL614357 | 0.77 | SYK (0.43) | JAK2SYKTTKRETSRC | |
| SCHEMBL612376 | 0.76 | SRC (0.46) | JAK3JAK2PTK2TTKRET | |
| SCHEMBL42448 | 0.76 | SRC (0.48) | JAK3JAK2PTK2TTKRET | |
| SCHEMBL614439 | 0.76 | TTK (0.42) | JAK3JAK2PTK2TTKSRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | claimed |
| US-20120041195-A1 | Heterocyclic compounds | FOVEA PHARMACEUTICALS | 2012-02-16 | — | — | US | disclosed |
| EP-2396324-A1 | Ý1, 2, 4¨TRIAZOLO Ý1, 5 -A¨PYRIDINES AS KINASE INHIBITORS | Fovea Pharmaceuticals (FR) | 2011-12-21 | — | — | EP | disclosed |
| WO-2010092041-A1 | [1, 2, 4] TRIAZOLO [1, 5 -A] PYRIDINES AS KINASE INHIBITORS | FOVEA PHARMACEUTICALS SA (FR) | 2010-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120041195-A1 | Heterocyclic compounds | MAP3K1, MAP3K5, MAP3K2 | JAK3 335/4885JAK2 325/4885PTK2 182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.